Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals

Affiliations

¹ Division of Hematology/Oncology, Department of Medicine, Columbia University Medical Center, Herbert Irving Pavilion, 9th Floor, 161 Fort Washington Avenue, New York, New York 10032, USA; and the James J. Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, New York 10468, USA.

Comment

Susan E Bates et al. Nat Rev Clin Oncol. 2016 Apr.

. 2016 Apr;13(4):205-6.

doi: 10.1038/nrclinonc.2016.22. Epub 2016 Feb 23.

¹ Division of Hematology/Oncology, Department of Medicine, Columbia University Medical Center, Herbert Irving Pavilion, 9th Floor, 161 Fort Washington Avenue, New York, New York 10032, USA; and the James J. Peters VA Medical Center, 130 West Kingsbridge Road, Bronx, New York 10468, USA.

No abstract available

Comment on

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Wang-Gillam A, et al. Lancet. 2016 Feb 6;387(10018):545-557. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Lancet. 2016. PMID: 26615328 Clinical Trial.